The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients

American Heart Journal

Volumn 164, Issue 1, 2012, Pages 72-79

  Dungu, Jason ^a,b   Sattianayagam, Prayman T ^a   Whelan, Carol J ^a   Gibbs, Simon D J ^a   Pinney, Jennifer H ^a   Banypersad, Sanjay M ^a   Rowczenio, Dorota ^a   Gilbertson, Janet A ^a   Lachmann, Helen J ^a   Wechalekar, Ashutosh ^a   Gillmore, Julian D ^a   Hawkins, Philip N ^a   Anderson, Lisa J ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOLEUCINE; PREALBUMIN;

ADULT; AFRICAN CARIBBEAN; AGED; ARTICLE; COMPLETE HEART BLOCK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ELECTRIC POTENTIAL; ELECTROCARDIOGRAPHY; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FOLLOW UP; GENETIC VARIABILITY; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE HYPERTROPHY; HEART PACING; HEART RHYTHM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CARDIOMYOPATHIES; CARIBBEAN REGION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREALBUMIN;

EID: 84863638985     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.04.013     Document Type: Article

References (34)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909. (Pubitemid 27408573)
2. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
3. Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-57. (Pubitemid 28102667)
4. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
5. Dungu J, O'Donnell M, Hawkins PN, et al. Systematic review of 1142 admissions with acute heart failure reveals high frequency of transthyretin V122I cardiac amyloidosis in Afro-Caribbean patients (abstract). J Am Coll Cardiol 2012;59:993, http://dx.doi.org/10.1016/S0735-1097(12)60994-2.
6. Gorevic PD, Prelli FC, Wright J, et al. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest 1989;83:836-43. (Pubitemid 19080614)
7. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet 1990;47:127-36.
8. Jacobson DR, Pastore R, Pool S, et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996;98:236-8. (Pubitemid 26237513)
9. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005;95:535-7. (Pubitemid 40247559)
10. Talmud P, Tybjaerg-Hansen A, et al. Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis 1991;89:137-41.
11. Booth DR, Tan SY, Hawkins PN, et al. A novel variant of transthyretin, 59Thr → Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation 1995;91:962-7.
12. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982;49:9.
13. Sokolow M, Lyon T. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-86.
14. Casale P, Devereux R, Kligfield P, et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 1985;6:572-80. (Pubitemid 16219234)
15. Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram. J Am Coll Cardiol 2009;53:992-1002.
16. Kafka H, Burggraf G, Milliken J. Electrocardiographic diagnosis of left ventricular hypertrophy in the presence of left bundle branch block: an echocardiographic study. Am J Cardiol 1985;55:103-6. (Pubitemid 15152531)
17. Vandenberg B, Sagar K, Paulsen W, et al. Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in the presence of complete right bundle branch block. Am J Cardiol 1989;63:1080-4. (Pubitemid 19117509)
18. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93. (Pubitemid 40139730)
19. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28. (Pubitemid 41098849)
20. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-9. (Pubitemid 40973426)
21. Chapman JN, Mayet J, Chang CL, et al. Ethnic differences in the identification of left ventricular hypertrophy in the hypertensive patient. Am J Hypertens 1999;12:437-42. (Pubitemid 29238404)
22. Spencer CGC, Beevers DG, Lip GYH. Ethnic differences in left ventricular size and the prevalence of left ventricular hypertrophy among hypertensive patients vary with electrocardiographic criteria. J Hum Hypertens 2004;18:631-6. (Pubitemid 39232347)
23. Lee DK, Marantz PR, Devereux RB, et al. Left ventricular hypertrophy in black and white hypertensives. Standard electrocardiographic criteria overestimate racial differences in prevalence. JAMA 1992;267:3294-9.
24. Rautaharju PM, Zhou SH, Calhoun HP. Ethnic differences in ECG amplitudes in North American white, black, and Hispanic men and women. Effect of obesity and age. J Electrocardiol 1994;27:20-31. (Pubitemid 124034256)
25. Agyemang C, Bhopal R. Is the blood pressure of people from African origin adults in the UK higher or lower than that in European origin white people? A review of cross-sectional data. J Hum Hypertens 2003;17:523-34. (Pubitemid 36949447)
26. Cushman WC, Ford CE, Cutler JA, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2000;4:393-404. (Pubitemid 35469393)
27. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010;56:780-800.
28. Kressin NR, Orner MB, Manze M, et al. Understanding contributors to racial disparities in blood pressure control. Circ Cardiovasc Qual Outcomes 2010;3:173-80.
29. Connors L, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607-14.
30. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70.
31. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91. (Pubitemid 34586914)
32. Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov 2002;1:267-75. (Pubitemid 37361443)
33. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9. (Pubitemid 34534701)
34. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93-7.